
CLAIMS

1. Use of a compound of formula (I):



or a pharmaceutically acceptable salt thereof, wherein the azo bond in the structure may be either cis or trans, in the manufacture of a medicament for treating a retinal disorder in a subject, wherein the medicament is to be administered to the eye of the subject by intravitreal injection.

2. The use of claim 1, wherein the retinal disorder is retinitis pigmentosa, age-related macular degeneration, or choroideremia.

3. The use of claim 1 or 2, wherein the medicament is to be administered to both eyes of the subject.

4. The use of claim 1 or 2, wherein the medicament is to be administered to one eye of the subject.

5. The use of claim 7, wherein administration to one eye of the subject provides a treatment effect to both eyes of the subject.

6. The use of claim 4 or 5, wherein a first administration of the medicament is to be made to one eye of the subject, and a second administration of the medicament is to be made to contralateral eye of the subject about 1 week to about 2 months after the first administration.

7. The use of claim 4 or 4, wherein a first administration of the medicament is to be made to one eye of the subject, and a second administration, of the medicament is to be made to the same eye of about 1 week to about 2 months after the first administration.

8. The use of any one of claims 1 to 7, wherein the medicament is to be administered to increase the subject's ability to detect light and contrast as measured by a light response test.

9. The use of any one of claims 1 to 8, wherein the medicament is to be administered to increase tolerance of glare and photosensitivity in the subject.

10. The use of any one of claims 1 to 9, wherein the medicament is to be administered to increase measures of functional vision, stimulate striate (V1) and non-striate (V2 and/or V3) cortical activity in the subject, reduce the non-specific, non-stimulus generated, random electrical activity of the retina, or combinations thereof.

11. The use of any one of claims 1 to 10, wherein the medicament further comprises a cyclodextrin.

12. The use of claim 11, wherein a molar ratio of cyclodextrin to the compound of formula (I) in the medicament is about 20:1 to about 1:1.

13. The use of any one of claims 1 to 12, wherein the concentration of the compound of formula (I) in the medicament is from about 0.1 mM to about 10 mM.

14. The use of any one of claims 1 to 13, wherein the about 1μg to about 100 μg of the compound of formula (I) is to be administered to a single eye.

15. The use of claim 4 or 5, wherein a second administration to the contralateral eye is to be made simultaneously or substantially simultaneously as the first administration, or is to be made immediately following the first administration.